|Bid||102.62 x 100|
|Ask||102.79 x 200|
|Day's range||101.40 - 119.00|
|52-week range||50.56 - 119.00|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2018 - 19 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||115.80|
AveXis Inc. shares dropped 6.4% in moderate morning trade Tuesday after the company announced plans for an up to $400 million secondary offering. AveXis also plans to grant the underwriters -- joint book-running ...
AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill Lynch are acting as joint book-running managers. BMO Capital Markets Corp. is acting as lead manager. AveXis intends to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less the underwriting discounts and commissions.
Biogen (BIIB) slipped to the bottom of the S&P 500 on Monday, following disappointing drug results from a competitor late Friday. Biogen lost $12.84, or 3.7%, to $321.65, while the S&P 500 gained 4.56 ...
Three companies developing replacement gene-therapy treatments provided updates last week on clinical trials. Investors were happy with the news at Audentes Therapeutics (BOLD), and disappointed with what they heard from Avexis (AVXS) and Regenxbio (RGNX). Replacement gene therapy has become one of the hottest areas of biotechnology in the past year because of optimism that one-time treatments aimed at replacing faulty genes with healthy ones could result in cures for a host of serious genetic diseases.
REGENXBIO Inc. (Nasdaq:RGNX) and AveXis, Inc. (Nasdaq:AVXS) today announced that they have entered into an amendment which expands upon the exclusive, worldwide license agreement they entered into in March 2014 (2014 License Agreement) for the development and commercialization of products to treat spinal muscular atrophy (SMA). AveXis’ initial proprietary gene therapy candidate, AVXS-101, is in a pivotal trial for the treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2.
Biogen and Ionis are unlikely to see a competitor to Spinraza in 2018, as rival AveXis faces a significant delay for its competing drug.
Shares of AveXis Inc. fell more than 7% late Thursday after the gene-therapy company said it was preparing to respond to Food and Drug Administration information requests about AveXis's primary gene therapy, ...
- Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD - - Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH - - Anticipate completing dosing and presenting topline data from RGX-314 and RGX-501 trials in late 2018 - - Anticipate initiating dosing in clinical trials for MPS I and MPS II in first half 2018 - - Ended 2017 with greater than $175 million in cash, cash equivalents and marketable securities -
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today provided an update following the receipt of minutes from the end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) conducted on December 5, 2017, regarding the company’s primary gene therapy candidate, AVXS-101, for the treatment of spinal muscular atrophy (SMA) Type 1. The goal of the end-of-Phase 1 meeting was to review the non-clinical, clinical and Chemistry, Manufacturing and Controls (CMC) data that has been generated by AveXis to date, and to align with the FDA on next steps leading to a Biologics License Application (BLA) submission. The FDA provided detailed information requests in each of the areas discussed, which the company plans to address by submitting the requested information to the investigational new drug (IND) application on an on-going basis.
Biotech AveXis Inc. could benefit, if indirectly, from payment arrangements set up by rival Spark Therapeutics Inc. for its $850,000-a-patient gene therapy Luxturna, RBC Capital Markets analyst Brian Abrahams ...
Biogen and Ionis sank after AveXis said it would start trials for a new spinal muscular atrophy treatment.
AveXis (AVXS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
On a per-share basis, the Bannockburn, Illinois-based company said it had a loss of $1.52. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
AveXis, Inc. , a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, announced data as of August 7, 2017, from the Phase 1 trial of AVXS-101 in patients with spinal muscular atrophy Type 1 were published today in the New England Journal of Medicine in a paper titled “Single-Dose Gene-Replacement Therapy for Spinal ...
AveXis touched a record high Tuesday, but PTC dove by double digits as each biotech presented updates on their spinal muscular atrophy programs.
CHARLOTTESVILLE, Va.--(BUSINESSWIRE)-- PBM Capital Group has completed the sale of a majority interest in Breas Medical Group (“Breas”) to Fosun Pharma (“Fosun”), a leading healthcare company in China. ...